Likewise, sensitivity to Bcl-xL inhibition has been observed in cell lines of pilocytic astrocytoma, the most common brain tumour in children, and adamantinomatous craniopharyngioma, the most common childhood pituitary tumour, suggesting a potential therapy against these tumours27,49. This evidence concerns the gene BCL2L1 and pituitary tumor.